{"entity":{"id":"nct06634056","kind":"trial","name":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","aka":["P4-PACIFIC"],"tldr":"A phase 2 trial in lung cancer, run by University Health Network, Toronto, now recruiting.","summary":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation is a phase 2, randomised interventional study registered as NCT06634056 by University Health Network, Toronto, with a registry enrolment figure of 150 participants, started 2026-06-15 and due to reach its primary completion in 2031-11-30. Interventions recorded: Pentoxifylline; Placebo; α-Tocopherol. Conditions listed: Non-Small Cell Lung Cancer; Radiation Induced Lung Injury (RILI). Primary outcome: Change in risk of Lung Injury. Lung eligibility wording from the registry: \"* Histologically confirmed diagnosis of stage III NSCLC, planned for treatment with concurrent chemoradiation and consolidation immune checkpoint inhibitor as per standard of care with no medical contraindications to therapy\". Sites: Canada. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06634056","url":"https://clinicaltrials.gov/study/NCT06634056"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["stage-iii-unresectable-nsclc"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06634056","phase":"2","setting":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","sponsor":"University Health Network, Toronto","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06634056/","neighbours":{"cancer":[{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}